Statistical meta-analyses of results from broiler pen trials and a few field trials published during 2009-2012 using dietary Actigen were conducted. Actigen (Alltech, Inc., Nicholasville, Kentucky, USA) is a second-generation, yeast cell wall product considered to be a "growth permitter" through its roles in immune modulation and improved intestinal health. Parameters evaluated were dietary inclusion rates for Actigen, age of birds, body weight, Feed Conversion Ratio (FCR) or feed/gain ratio (F/G ratio) and mortality %. Eighteen reports were collected allowing 29 comparisons of negative control (nCON) diets and Actigen supplemented diets (200 to 800 g/tonne) fed during the entire trials. Similarly, 15 reports were collected allowing 20 comparisons of positive control (antibiotic supplemented) diets and Actigen supplemented diets (200 to 882 g/tonne). When added to basal diets continuously to an average broiler age of 41.72 days (n = 29), Actigen significantly and beneficially changed body weight by +0.0.80 kg (+3.34%), FCR or F/G ratio by -0.033 (-1.84%) and mortality % by -0.80 (-12.5% relative to nCON). Compared with positive control (antibiotic) results, dietary Actigen fed continuously to an average broiler age of 42.73 days (n = 20) gave results statistically equivalent with those of dietary antibiotics. Comparisons between this present metaanalysis and those done previously on another yeast cell wall compound (Bio-Mos) suggest that the second generation product Actigen may be more effective in terms of growth promotion.
INTRODUCTION
To keep coccidiosis and bacterial diseases such as necrotic enteritis under control when broiler chickens are Kentucky, USA introduced the first generation produced on litter, dietary coccidistats or vaccines and various antibiotic growth promoters or alternative products are used. Bacitracin methylene disalicylate (BMD , Alpharma, Inc., Fort Lee, New Jersey, USA) is ® selective in its action in that it affects only Gram-positive microbes such as streptococci, staphylococci and clostridia. Bacitracin suppresses synthesis and induces lysis of bacterial cell walls, interferes with synthesis of protoplastic proteins within the cells and reduces toxin production by certain bacteria resulting in less inflammation of the gut (International Minerals and Chemicals Corporation, ca. 1978) . Virginiamycin (Stafac , Phibro Animal Health, 2010 ) is a streptogramin ® antibiotic approved for broiler chickens at 5 g/ton (2, 000 lb) to improve feed conversion ratio, 5-15 g/ton t o improve weight gain and 20 g/ton for prevention o f necrotic enteritis caused by Clostridium perfringens susceptible to virginiamycin. The use of low-level antibiotics such as bacitracin and virginiamycin have come under pressure from consumers of chicken due to concern about antibiotic resistant bacteria and the potential diminished effectiveness of antibiotics used for humans. Mannan oligosaccharide from yeast outer cell wall has been used as a dietary supplement in broiler feeds (Kumprecht et al., 1997; Waldroup et al., 2003; Rosen, 2007) since about 1993 when Alltech, Inc., Nicholasville, commercial product (Bio-Mos). Oligosaccharides are carbohydrates which on hydrolysis yield about 2 to 10 monosaccharides. The idea to use yeast mannan oligosaccharide in poultry feeds evolved from the concept that certain sugars, particularly mannose, largely block the colonization of intestinal pathogens such as Salmonella species and Escherichia coli which contain type 1 fimbrae, from attaching to intestinal mannose, proliferating and producing toxins and damage. Some of the demonstrated modes of action of dietary mannan oligosaccharide include: 1. Binding of enteric pathogens with Type 1 fimbrae (mannose seeking lectins) and thus blocking their adhesion to the gut lining (Eshdat et al., 1978; Spring et al., 2000) 2. Modifying microflora fermentation (less propionic acid and ammonia production) to conserve nutrients for the bird to utilize (Ferket et al., 2005) 3. Maintaining integrity of gut lining and improved gut health such as greater villi height (Iji, 2001) , more goblet cells/mm villus height thus increasing the brush border mucin barrier and thinner muscularis layer (Ferket et al., 2005) 4. Immune modulation enhancing immune responses response, inflammatory response and antimicrobial (adjuvant effect and liver secretion of mannose-responses such as toll-like receptor signaling, interferon binding protein to bind bacteria and initiate the signaling and retinoic acid inducible protein-1 (R1G1) complement cascade of the bird's immune system) receptor mediated innate immunity. Significant (Savage et al., 1996; Cotter et al., 2002; Shashidhara upregulation of such genes as toll-like receptor 3 Ferket et al., 2005) .
(TLR3), myxovirus resistance 1 (MX1), Interferon The presence of dietary mannan oligosaccharide and Regulatory Factor 7 (IRF7), suppressor of cytokine pathogens together in the lumen of the intestine signaling 1 (SOCS1) and down-regulation of ADPfunctions as an adjuvant and antigen system, allowing ribosyltransferase (CHAT2) further indicated that Actigen enhanced antigenicity and superior immune response had modulatory effects on the intestinal immune system (Shafey et al., 2001) . Xiao et al., 2011) . A second-generation yeast outer cell wall specific- Brennan et al. (2010) compared the effects o f compound derived product is Actigen (Alltech, Inc., supplementing Actigen or BMD to the diet on mRNA Nicholasville, Kentucky, USA). This was developed using levels of mucin and mucin-regulating genes in the nutrigenomics technology (gene chips) which allows jejunum of 42-day old broiler chickens. The mRNA levels detection of changes in expression of genes in intestinal of mucin 2 (cMUC2) tended to be 1.29-fold greater in cells. Internal trials by Alltech confirmed this to be at Actigen-and BMD -treated birds than controls (p<0.10). least 2.5 more times more concentrated in biological
The mucin 2 gene encodes a protein component of the activity than the first generation mannan product (Bio-mucosal layer that protects the intestinal cell wall from Mos). The higher activity is clearly what makes this bacterial translocation. Change in mucin 2 mRNA levels compound unique. Actigen is typically supplemented to corresponded to changes in goblet cells and reflected a broiler chicken feeds at 200 to 800 g/tonne which is beneficial change in gut health. Analysis of tissue about 40% of the original product's inclusion rate.
morphology indicated that supplementation with either Actigen is considered to be a "growth permitter" through Actigen or BMD resulted in an increased villus height, its roles in immune modulation and improved intestinal goblet cell count and an increased villus height to crypt health. The units of activity in the commercial product depth ratio in the jejunum (Collett et al., 2011) . The may be determined by rapid kit test developed by Alltech, mRNA levels of mucin-regulating genes interleukin 18 Inc. and a separate in-feed assay is also available to (IL18) and keratinocyte growth factor 7 (KGF7) were confirm quantitatively and qualitatively the presence of similar between Actigen-and BMD -treated birds. The the product.
toll-like receptors 2 and 5 (TLR2 and TLR5), two key Changes in gene expression in the gut mucosa o f markers for pathogenic insult in the gut, had mRNA broiler chickens fed diets containing Actigen (400 levels greater by 1.20-fold and 1.23-fold respectively in g/tonne) and/or bacitracin methylene disalicylate (BMD BMD -treated birds than in controls (Brennan et al., ® 50 g/ton) have been studied Xiao 2010 Xiao ). et al., 2011 . Genes involved in protective functions and
The objective of this meta-analysis summary article was pathways were influenced by Actigen and/or BMD .
to c ollect and statistically analyze by paired t-test ® Microarray analysis revealed that when birds were [Statistix 8®, (2003) Analytical Software, Inc., supplemented with Actigen, 928 genes were Tallahassee, Florida, USA] broiler feeding trial results significantly changed (P<0.05, FC>1.2; 456 down-worldwide from 2009-2012 to compare negative control regulated, 472 up-regulated) while BMD (basal diets) or positive control (antibiotic-® supplementation resulted in 857 genes that significantly supplemented) diets with Actigen-supplemented diets. changed (408 down-regulated, 449 up-regulated).
The studies included pen trials and field trials. Surprisingly, 316 genes were commonly and significantly changed by Actigen and BMD (146 down-® regulated, 170 up-regulated). When differentially affected genes (that is, up-regulated or down-regulated) were grouped by biologic function, it was found that Actigen and BMD commonly altered ® genes involved in antimicrobial response, inflammatory response and infection mechanism, cell-to-cell signaling and interaction and cellular development. Gene ontology analysis showed that a broad range of biological functions were associated with the altered gene expressions. Pathway analysis suggested a strong connection between Actigen and up-regulation of signaling pathways directly involved in cellular immune
MATERIALS AND METHODS
Worldwide broiler chicken pen trial reports (2009-2012) were analyzed statistically to determine effects of Saccharomyces cerevisiae var. boulardii yeast outer cell wall specific-compound derived product (Actigen, Alltech, Inc., Nicholasville, Kentucky, USA) on live performance.
Actigen was developed using nutrigenomics technology which allows detecting changes in expression of genes in intestinal cells. Criteria for selecting studies were: 1. Written report 2. Antibiotic(s) or Actigen were fed for the entire trial 3. Age of birds (duration of trial) 4. Negative (basal) and/or positive (antibiotic) control (ACT) diets. There were 18 written reports providing 29 5. Antibiotic stated for positive control comparisons of results from these 2 treatments. The 6. Body weight and feed conversion ratio (FCR) o r average age (and trial duration) was 41.72 days. feed/gain ratio (F/G ratio) results were given (and Average inclusion rates for Actigen by phases varied mortality % was included when reported).
from 800 to 200 g/tonne and it was fed during the entire Results were analyzed by treatments using paired t-test trial in each case. Body weight was very highly in S tatistix 8® software (Analytical Software, Inc., significantly (p<0.001) greater for the ACT birds than for Tallahassee, Florida, USA).
nCON birds (+0.080 kg; +3.34%). The feed conversion Table 1 is a summary of live performance results from broiler chicken trials with negative control (nCON) versus Actigen-supplemented ratio (FCR) or feed/gain ratio (F/G ratio) was very highly significantly (p<0.001) decreased for ACT birds compared to nCON birds (-0.033; -1.84). Mortality % was significantly (p = 0.031) reduced for Actigen birds compared to nCON birds (-0.80%; -12.5% relative to nCON). Actigen Actigen in starter 0-15 days, grower 15-28 days and finisher 28-38 days. 5 Actigen in starter 0-17 days, grower 7-31 days and finisher 31-52 days. 6 Actigen in starter 0-18 days, grower and finisher 18-61 days. 7 Actigen in prestarter about 0 to 7-10 days, starter to day 18-19, grower to day 30, then finisher to 40-41 days. 8 Actigen in starter 0-7 days, grower 7-21 days and finisher 21-42 days. 9 Feed phase ages not given; mortality % from 0-32 days. 10 Actigen in starter, grower and finisher 1 and 2 feeds (ages not given). 11 Table 2b : Antibiotics programs used in obtaining broiler trial results presented in Table 2a Reference ( ZnBacitracin 0-10 days 100 mg/kg; 10-35 days 50 mg/kg "Tonne" is metric ton (1, 000 kg or 2, 204.6 lb) and "ton" is U.S. ton (907.19 kg or 2, 000 lb). 1 Antibiotic growth promoter (AGP) diets versus Actigen supplemented (AGP) diets versus Actigen (ACT) diets: Listed in Table 2a are the broiler chicken supplemented (ACT) diets. Average age (and trial live performance results from 15 written reports duration) was 42.73 days. Average inclusion rates for providing 20 comparisons of antibiotic growth promoter Actigen by phases varied but ranged from 200 to 882 (2007) reported a holo-analysis of broiler chicken trial in each case. All of the live performance results for AGP and ACT were statistically equivalent (within the same statistical groupings) showing no significant differences and differences were quite small. The antibiotic growth promoters and dietary inclusion rates pertaining to results in Table 2a are given in Table  2b . The antibiotic growth promoters used in the trials included Surmax (Avilamy-cin), BMD , BMD / Stafac ® ® ® ® and zinc bacitracin.
RESULTS

Negative control (nCON) diets versus Actigen (ACT) diets: Presented in
(%) Age, Actigen ------------------------- ------------------------- ---------------------- days g/tonne nCON ACT nCON ACT nCON ACT Reference (Yaer)------------------------- ------------------------- ------------------------------------------------------------------------------------------------------------------
DISCUSSION
Actigen is a second generation product containing Mannan Oligosaccharide (MOS), a specific compound derived from the cell wall of yeast ( Saccharomyces cerevisiae var. boulardii). In-feed assays and product +0.050 kg (+2.43%) for broiler body weight and of -0.033 assays allow the confirmation of the active ingredient quantitatively and qualitatively (through ELISA technology). These are key points in differentiating Actigen from the MOS feed additive products which have gone before it. Hooge (2004) conducted meta-analyses of broiler chicken pen trials evaluating dietary mannan oligosaccharide from 1993-2003 and all trials involved supplementation of feeds with the first generation product Bio-Mos (Alltech, Inc., Nicholasville, Kentucky, USA) from which Actigen was derived (see Table 3 ). Compared to broiler results using negative control diets, Bio-Mos diets significantly (p = 0.020) improved body weight by 0.038 kg or +1.75%, feed conversion ratio by -0.035 or -1.89% and mortality % by -0.759% actual or -16.4% relative to negative control. Nonsignificant (p = 0.408) changes using Bio-Mos diets compared to antibiotic growth promoter diets were -0.007 kg or -0.32% relative to antibiotic control in body weight and -0.008 or -0.11% in feed conversion ratio. The Bio-Mos diets highly significantly (p = 0.007) changed mortality % by -0.83% actual and -18.1% relative to the antibiotic growth promoter diets, indicating a strong beneficial effect. trials from 1997-2003 evaluating dietary mannan oligosaccharide product Bio-Mos versus negative control (see Table 3 ). From multiple regression equations, body weight was 0.0276 kg (1.48%) greater, feed conversion ratio was 0.0391 (2.11%) lower and mortality was 0.0311% (actual) (0.43% relative to negative control) higher with Bio-Mos diets compared to negative control diets. Beneficial response frequencies with dietary Bio-Mos were 65, 70 and 52%, respectively, for these 3 parameters. Hooge (2009) prepared a meta-analysis of 48 additional comparisons beyond those included in the Hooge (2004) article and found significant improvements with Bio-Mos diets compared to negative control diets of (-1.76%) for feed conversion ratio (Table 3) . Mortality % was statistically equivalent for these 2 treatments (+0.12% actual mortality for Bio-Mos group, or +1.44% higher relative to negative control). In the present summary reported herein, body weight was greater (p<0.001) for the Actigen (ACT) fed birds than for the negative control (nCON) fed birds (+0.080 kg; +3.34%), feed conversion ratio (FCR) or feed/gain ratio (F/G ratio) was lower (p<0.001) for ACT-fed birds than for nCON-fed birds (-0.033; -1.84) and mortality % was significantly (p = 0.031) reduced by dietary ACT. The ACT birds had 0.80% lower mortality which amounted to a 12.5% relative reduction in mortality % compared to nCON birds. There was a non significant (p = 0.771) and only slight difference of -0.005 kg (-0.19%) in body weight in favor of the AGP treatment compared to the ACT treatment. The Feed Conversion Ratio (FCR) or feed/gain ratio (F/G ratio) averages were identical for the ACT and AGP groups. Mortality % was not significantly different (p = 0.935) for ACT and AGP fed groups (-0.05% actual for ACT-fed birds, amounting to -0.82% decline relative to AGP mortality result). All of the live performance results for AGP and ACT were statistically equivalent (that is, within the same statistical groups). (2004), Rosen (2007) and Hooge (2009) in comparison with Actigen meta-analysis results obtained from this current exercise. Bozkurt et al. (2009) found significantly improved body weight and feed conversion ratio at 21 and 42 days in male broilers fed a mannan oligosaccharide product (Bio-Mos, 0.1%) compared to negative control broilers. De Oliveira et al. (2009) fed dietary mannan oligosaccharide at 0.1% from 0-21 days and 0.05% from 21-42 days and found that litter ammonia volatilization decreased when mannan oligosaccharide diets were fed versus unsupplemented diets. Mathis (2011b) reported results of a pen trial conducted on 10.2 cm (4 in.) built-up litter top dressed with pine shavings and using straight-run Cobb chicks. Three dietary treatments were: (1) Negative control (2) Actigen at 800 g/tonne 0-7 days, 400 g/tonne 7-21 days and 200 g/tonne 21-42 days and (3) BMD at 50 g/ton 0-21 days ® and 25 g/ton 21-42 days. Salinomycin at 50 g/ton (0-21 days) and 60 g/ton (21-35 days) was the coccidiostat. Intestinal villus height, villus height: Crypt depth ratio and goblet cell count were increased (p<0.010) and litter scores were improved (p<0.001), when birds were fed ACT or BMD vs. nCON. Improved intestinal morphology ® of broilers fed dietary mannan oligosaccharide has been observed by several other researchers as well (for example : Iji, 2001; Yang et al., 2008; de Oliveira et al., 2009) .
Conclusion:
This meta-analysis summary of 18 reports with 29 comparisons of Actigen diets vs. negative control (basal) diets suggests that Actigen may be effective as a dietary growth promoter/ permitter for broilers due to the significant increases in average body weight (+0.080 kg) and decreases in average feed conversion ratio (-0.033) and mortality % (-0.80% actual) observed. Statistically equivalent broiler live performance improvements were found in this meta-analysis for Actigen fed groups vs. antibiotic fed groups and results were quite close (15 reports, 20 comparisons). I n conclusion, these results give indication of the broiler live performance benefits to be expected when using Actigen diets vs. basal diets or those supplemented with various antibiotic growth promoters.
